- Home
- DDI vs DMAC Comparison
DDI vs DMAC Comparison
Compare DDI & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DDI
- DMAC
- Stock Information
- Founded
- DDI 2008
- DMAC 2000
- Country
- DDI South Korea
- DMAC United States
- Employees
- DDI N/A
- DMAC N/A
- Industry
- DDI EDP Services
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- DDI Technology
- DMAC Health Care
- Exchange
- DDI Nasdaq
- DMAC Nasdaq
- Market Cap
- DDI 472.2M
- DMAC 310.1M
- IPO Year
- DDI 2021
- DMAC N/A
- Fundamental
- Price
- DDI $9.31
- DMAC $6.87
- Analyst Decision
- DDI Strong Buy
- DMAC Strong Buy
- Analyst Count
- DDI 5
- DMAC 3
- Target Price
- DDI $19.60
- DMAC $12.33
- AVG Volume (30 Days)
- DDI 46.4K
- DMAC 448.5K
- Earning Date
- DDI 11-10-2025
- DMAC 11-12-2025
- Dividend Yield
- DDI N/A
- DMAC N/A
- EPS Growth
- DDI N/A
- DMAC N/A
- EPS
- DDI 2.15
- DMAC N/A
- Revenue
- DDI $333,256,000.00
- DMAC N/A
- Revenue This Year
- DDI $16.04
- DMAC N/A
- Revenue Next Year
- DDI $6.72
- DMAC N/A
- P/E Ratio
- DDI $4.35
- DMAC N/A
- Revenue Growth
- DDI 0.24
- DMAC N/A
- 52 Week Low
- DDI $8.09
- DMAC $3.19
- 52 Week High
- DDI $18.21
- DMAC $7.49
- Technical
- Relative Strength Index (RSI)
- DDI 42.51
- DMAC 63.84
- Support Level
- DDI $9.20
- DMAC $6.83
- Resistance Level
- DDI $9.74
- DMAC $7.41
- Average True Range (ATR)
- DDI 0.22
- DMAC 0.43
- MACD
- DDI -0.02
- DMAC 0.03
- Stochastic Oscillator
- DDI 11.70
- DMAC 73.62
About DDI DoubleDown Interactive Co. Ltd. American Depository Shares
DoubleDown Interactive Co Ltd is a developer and publisher of digital games on mobile and web-based platforms. The company is the creator of multi-format interactive entertainment experiences for casual players. The company's operating segments include the social casino games segment and the iGaming segment. The company generates the majority of its revenue from social casino games. Geographically, the company generates the majority of its revenue from the United States.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.